更新于：2024-11-01

Acute vomiting

急性呕吐

更新于：2024-11-01

基本信息

别名

Acute vomiting、Acute vomiting (disorder)、acute vomiting

简介-

关联

项与急性呕吐相关的药物

Levosulpiride

左舒必利

靶点

DRDs

作用机制

DRDs拮抗剂

在研机构

KOREA UNITED PHARM, Inc.

原研机构-

在研适应症

消化不良 [+2]

非在研适应症

急性呕吐 [+4]

最高研发阶段批准上市

首次获批国家/地区

意大利

首次获批日期2003-08-13

项与急性呕吐相关的临床试验

CTR20200963 / Completed临床3期

评价注射用福沙匹坦双葡甲胺用于预防高致吐性化疗所致的恶心、呕吐的有效性及安全性III期临床试验

以阿瑞匹坦胶囊为对照药，评价注射用福沙匹坦双葡甲胺用于预防高致吐性化疗所致的恶心、呕吐的有效性及安全性。

开始日期2020-06-08

申办/合作机构

宜昌人福药业有限责任公司

CTR20132118 / Completed临床2期

左舒必利注射液治疗急性呕吐随机、单盲、阳性药平行对照、多中心临床试验

以盐酸甲氧氯普胺注射液为对照，评价左舒必利注射液治疗急性呕吐的有效性和安全性。

开始日期2014-03-10

申办/合作机构

海南四环医药有限公司

[+2]

100 项与急性呕吐相关的临床结果

登录后查看更多信息

100 项与急性呕吐相关的转化医学

登录后查看更多信息

0 项与急性呕吐相关的专利（医药）

登录后查看更多信息

321

项与急性呕吐相关的文献（医药）

2024-10-01·The Canadian veterinary journal = La revue veterinaire canadienne

Peritoneal pericardial diaphragmatic hernia with an incidental finding of suspected right ventricular wall aneurysms in a dog.

Article

作者: Owen, Tina J ; Baumwart, Ryan ; Fracka, Agnieszka B ; Sharma, Surabhi

A 3-year-old neutered male standard poodle mix dog was presented because of acute onset vomiting, increased respiratory effort, hyporexia, and progressive lethargy. On physical examination, intermittent tachycardia, tachypnea with mildly increased respiratory effort, and bilateral ventral muffled lung sounds were noted. Thoracic and abdominal computed tomography with contrast revealed a peritoneal pericardial diaphragmatic hernia (PPDH) with herniation of the liver and gallbladder, moderate abdominal lymphadenopathy, and mild pleural effusion. The dog underwent an emergency laparotomy and median sternotomy. Right ventral PPDH with a herniated, necrosed, and nonviable quadrate liver lobe and gallbladder; 2 suspected right ventricular (RV) aneurysms; and generalized mesenteric and portal lymphadenopathy were present. The affected liver lobe and gallbladder were removed; suspected aneurysms were managed by placing 2 purse-string sutures around the lesions and anchoring a pericardial flap over the aneurysms. The dog developed a ventricular arrhythmia postoperatively. Due to the arrhythmia and intraoperative findings of suspected aneurysms, echocardiography was performed and revealed focal RV systolic dysfunction, left ventricular systolic dysfunction, mild left ventricular dilation, and a hyperechoic area on the RV free wall, consistent with the purse string. An angiotensin-convertingenzyme (ACE) inhibitor was prescribed for left ventricular dilation. The dog was discharged 4 d postoperatively and was doing well 12 mo postoperatively. To our knowledge, this is the first report of a PPDH and suspected concurrent RV wall aneurysm in a dog successfully treated with a purse string and pericardial flap. Key clinical message: An RV aneurysm is extremely rare yet can be life-threatening in small animals. Early detection and treatment may minimize the risk of aneurysm rupture and sudden death.

2024-10-01·International Journal of Gynecologic Cancer

Long-term survival in patients with para-aortic metastatic cervical cancer receiving simultaneous integrated boost chemoradiation to positive lymph nodes: a single-center experience

Article

作者: Wu, Haijing ; Qi, Zhongchun ; Li, Xiaokai ; Wang, Shuai ; Zhang, Yue ; Gao, Hui ; Wang, Mingyi

ObjectivesTo examine the benefits of extended-field chemoradiation with simultaneous integrated boost to positive lymph nodes, followed by image-guided adaptive brachytherapy in patients with cervical cancer with para-aortic metastasis.MethodsThis retrospective cohort study enrolled 143 patients diagnosed between January 2011 and July 2023 at a single center. Survival and recurrence were evaluated using the Kaplan-Meier method and log-rank test. Cox regression was employed to identify prognostic factors and adjust for confounding factors. Patients were then stratified according to neoadjuvant chemotherapy, and its impact on survival outcomes was evaluated.ResultsA total of 129 patients completed the entire treatment course. The 5-year overall survival rate was 57.6%, and the para-aortic failure rate was 6.8% after a median follow-up of 61 months (95% CI 49 to 82 months). Multivariate analysis indicated that neoadjuvant chemotherapy, larger primary tumor or pelvic/para-aortic lymph nodes, and lower hemoglobin nadir (for widespread metastasis-free survival only) predicted poorer survival. After propensity score matching, the 5-year para-aortic recurrence-free, widespread metastasis-free, and overall survival rates were 92.2% vs 92.8% (p=0.85), 50.8% vs 72.1% (p=0.007), and 47.5% vs 65.5% (p=0.037), respectively, in groups receiving neoadjuvant chemotherapy or not. Sixteen patients (12.4%) experienced grade 3–4 late toxicities. Patients who received neoadjuvant chemotherapy had a significantly higher incidence of grade 3–4 anemia and neutropenia than those who did not (45.2% vs 26.7% and 38.1% vs 21.8%, respectively), if including another 14 patients who discontinued treatment due to acute vomiting.ConclusionChemoradiation with simultaneous integrated boost to positive lymph nodes demonstrates favorable outcomes and acceptable late toxicities in para-aortic metastatic cervical cancer. Neoadjuvant chemotherapy has been shown to adversely affect outcomes, and acute vomiting is a major cause of treatment abortion.

2024-09-17·Cureus

Atypical Presentation of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: When Gastrointestinal Symptoms Obscure the Diagnosis

Article

作者: Ko Ko, Eingyin ; Thaw, Khine Min ; Kazi, Ashar U

The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe cutaneous adverse reaction. Due to its unfamiliarity, non-specific diagnostic criteria, and delayed onset, this condition is frequently overlooked, which can sometimes result in life-threatening consequences. DRESS typically manifests as an extensive mucocutaneous rash with multi-organ involvement. This report aims to emphasize the varied presentation of the syndrome. Our patient was initially presented with acute onset vomiting, abdominal pain, fever for a couple of days with a minor skin rash. At first, she was treated for acute viral gastritis. However, on her second presentation within a week, she had a more extensive skin rash. Upon detailed history, it was found that this was linked to the initiation of sulfasalazine for ulcerative colitis. RegiSCAR (Registry of Severe Cutaneous Adverse Reactions) scoring suggested it as a definite case of DRESS. The primary manifestation of gastrointestinal symptoms led to a delayed diagnosis. Still, it is important to consider the possibility of drug hypersensitivity when there are skin changes and blood abnormalities present.

项与急性呕吐相关的新闻（医药）

2024-09-09

·石药集团

石药集团阿瑞匹坦注射液获药品注册批件

9月9日，石药集团（1093.HK）公告，本集团开发的阿瑞匹坦注射液 (18ml:130mg)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。该产品是一种NK1受体拮抗剂的亚微乳注射剂，可与大脑中NK1受体高选择性地结合并拮抗P物质，以有效预防急性和迟发性呕吐。该产品适用于成年患者预防高度致吐性抗肿瘤化疗 (HEC) 和中度致吐性抗肿瘤化疗 (MEC) 引起的恶心和呕吐。与已上市口服制剂相比，该产品可实现单次给药，而且生物利用度高。与福沙匹坦制剂相比，该产品不含吐温80，可有效降低临床使用中过敏反应的发生率。此外，该产品除可以静脉滴注给药外，还具备静脉推注的给药方式，提供更多用药选择，更加高效便捷。该产品是本集团纳米制剂技术平台的第7个上市产品，本次获批将进一步丰富本集团抗肿瘤相关治疗领域的产品线。

申请上市上市批准

2024-07-08

·恒瑞医药

2024 MASCC/ISOO︱恒瑞创新药HR20013预防高致吐性化疗所致恶心和呕吐相关研究数据发布

2024年国际癌症支持治疗协会和国际口腔肿瘤学会联合年会（MASCC/ISOO）于近日在法国里尔顺利召开。本次大会作为肿瘤支持治疗的高级别会议，集中呈现了肿瘤支持治疗的全球最新进展。由中山大学肿瘤防治中心张力教授牵头，全国68家研究中心共同参与的“评价注射用HR20013用于预防高致吐性化疗引起恶心呕吐的有效性和安全性研究——多中心、随机、双盲双模拟、阳性对照Ⅲ期临床研究（PROFIT）”健康相关生活质量（QoL）结果在大会上发布。研究结果显示1，与福沙匹坦+帕洛诺司琼+地塞米松（FAPR+PALO+DEX）相比，对于接受高致吐性化疗（HEC）的患者，HR20013+地塞米松（DEX）具有改善患者QoL的潜力，尤其在延迟期和超延迟期。研究背景最新数据显示，我国恶性肿瘤年新发患者482.47万人，死亡患者257.42万人2。对于恶性肿瘤的综合预防和控制仍是我们当下需要面对的问题。近年来，新的抗肿瘤治疗方案和药物不断开发，但抗肿瘤治疗相关的恶心呕吐仍然是常见不良反应。尤其是化疗引发的恶心呕吐（CINV），会使患者对化疗产生恐惧，降低患者依从性，进而影响患者的生存获益。在CINV发病机制中，5-羟色胺3（5-HT3）受体和神经激肽受体1（NK-1）起到关键作用3。以顺铂为代表的的高致吐性化疗（HEC）导致急性呕吐发生率＞90%3。目前国内外指南针对高致吐性化疗（HEC）相关CINV的预防，推荐的是以5-羟色胺3受体拮抗剂（5-HT3 RA）和神经激肽受体1拮抗剂（NK-1 RA）为基础的三联/四联方案3、4。但在实践中针对高致吐性化疗（HEC）相关CINV的预防，联合用药繁琐，且依从性低。如何简化临床用药管理、提高患者的用药依从性和指南依从性，仍是有待进一步解决的问题。 HR20013是由恒瑞医药自主研发的Ⅰ类新药，目前首批适应症上市申请已被CDE受理。HR20013是HRS5580（新型NK-1拮抗剂）和帕洛诺司琼（PALO）的新型混合制剂，是一款新型超长效止吐产品，可同时拮抗NK-1和5-HT3受体，从而发挥止吐作用。HR20013仅需每个周期用药一次，简化了用药管理，兼顾了安全有效性和依从性。研究方法本研究共入组754例未经历化疗的恶性实体瘤患者（750例接受药物治疗），随机分为两组，在每周期给与顺铂为基础的高致吐性化疗（共2个周期）前，分别接受HR20013或福沙匹坦+帕洛诺司琼（FAPR+PALO）治疗，同时口服地塞米松（DEX）（D1-D4）。主要终点：第1个化疗周期顺铂开始给药后总体期（0-120h）完全缓解（CR）的受试者比例。研究设计如图1。本研究已达到主要终点，相关疗效数据已投稿2024年世界肺癌大会（WCLC）。本次大会主要介绍患者健康相关生活质量（QoL）数据。与QoL相关的终点是第1个周期和第2个周期中呕吐生活功能量表（FLIE）评分的变化和对日常生活无影响（NIDL）报告的患者比例。在基线、HEC开始后24、120和168小时进行FLIE问卷。NIDL定义为总体FLIE评分>108；或恶心/呕吐评分>54。图1. 研究设计图研究结果两组患者基线特征具有可比性。HR20013+地塞米松（DEX）组和福沙匹坦+帕洛诺司琼+地塞米松（FAPR+PALO+DEX）组分别有373例和377例患者接受第1个周期的研究治疗，分别有314例和336例患者接受第2个周期的研究治疗。在第1周期中，两组总体/恶心/呕吐FLIE评分较基线的变化差异均无统计学意义（所有的P>0.05；图2）。在第2周期中，HR20013+DEX与FAPR+PALO+DEX相比，在延迟期总评分（24-120h；LS均值分别为-3.5 vs 6.0；P=0.03）、延迟期呕吐评分（-1.2 vs -2.4；P=0.03）、超延迟期恶心评分（120-168h；-1.1 vs -2.1；P=0.04）相比基线下降幅度较小（图3）。图2（左）第1周期FLIE评分的变化:总评分（A）、恶心评分（B）和呕吐评分（C）图3（右）第2周期FLIE评分的变化:总评分（A）、恶心评分（B）和呕吐评分（C）第1周期，在所有的3个阶段中[急性期（0-24h）、延迟期和超延迟期]两组的NIDL患者报告比例，在整体域、恶心域和呕吐域大体相当（所有的P>0.05；图4）。在第2周期中，HR20013+DEX组与FAPR+PALO+DEX组相比，整体域延迟期（93.6% vs 87.8%；P=0.01）、呕吐域延迟期（95.2% vs 90.8%；P=0.03）、整体域超延迟期（96.8% vs 92.9%；P=0.03）、恶心域超延迟期（95.9% vs 91.1%；P=0.02）NIDL患者报告比例更高（图5）。图4 第1周期基于FLIE评分的NIDL患者报告比例图5 第2周期基于FLIE评分的NIDL患者报告比例研究结论与福沙匹坦+帕洛诺司琼+地塞米松（FAPR+PALO+DEX）相比，对于接受高致吐性化疗（HEC）的患者，HR20013+地塞米松（DEX）具有改善患者健康相关生活质量（QoL）的潜力，尤其是在延迟期和超延迟期。参考文献： 1. L.Zhang,2024 MASCC/ISOO,P2009. 2.Zheng RS,Chen R,Han BF,et al.[Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi.2024 Mar 23;46(3):221-231. 3.Antiemesis,NCCN Guidelines,2024 V1. 4.China Anti-Cancer Association Committee of Rehabilitation and Palliative Care; China Anti-Cancer Association Committee of Tumor Clinical Chemotherapy; China Anti-Cancer Association Committee of Neoplastic Supportive-Care; Chinese Society of Clinical Oncology Committee of Supportive and Rehabilitative Care. [China guidelines on prevention and treatment of nausea and vomiting caused by antitumor therapies (2023 edition)].Zhonghua Zhong Liu Za Zhi. 2024 Jun 23;46(6):481-501. 声明： 1.本新闻旨在分享学术前沿动态，仅供医疗卫生专业人士基于学术目的参阅，非广告用途。 2.恒瑞医药不推荐任何未被批准的药品、适应症的使用。撰稿：中央医学事务部排版：马瑞璘责编：李玉莹往期精选 | 研发创新 | 恒瑞医药新突破！中国首个自研阿片类镇痛创新药富马酸泰吉利定获批上市代谢领域再下一城！恒瑞医药糖尿病创新药瑞格列汀（瑞泽唐®）获批 | 国际化 | 海外BD再传捷报！恒瑞医药GLP-1类创新药组合实现海外许可恒瑞医药与默克达成合作，携手推进癌症创新疗法 | 重磅奖项 | 喜报！恒瑞医药荣获2023年度国家科技进步奖恒瑞医药连续六年入选全球制药企业50强榜单！ | 社会公益 | “健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

临床3期申请上市上市批准